Allergies News and Research

Latest Allergies News and Research

Immunity, Inflammation and Disease journal from Wiley

John Wiley & Sons, Inc., announced today the launch of a new open access, interdisciplinary journal providing rapid publication of cutting-edge research across the broad field of immunology.

5 Mar 2013

Eating your greens may be even more important than previously thought

Eating your greens may be even more important than previously thought, with the discovery that an immune cell population essential for intestinal health could be controlled by leafy greens in your diet.

5 Mar 2013

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

Two million Americans are allergic to insect stings, an allergy which sends more than 500,000 people to the emergency room annually. Yet, according to a study published today in the March issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAA), while fire ant allergy sufferers know allergy shots can save their life, more than 60 percent do not adhere to treatment guidelines.

4 Mar 2013

DBV Technologies total revenues increase to €2,776,588 for full year 2012

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today its full year 2012 results, approved by the Board of Directors on March 1st, 2013.

4 Mar 2013

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Sanofi and Regeneron Pharmaceuticals, Inc. announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting of the American Academy of Dermatology (AAD) in Miami.

4 Mar 2013

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Amoxicillin is a broad spectrum penicillin, and in the UK is one of the most frequently used antibiotics. It is commonly used either on its own or, where there are particular concerns about resistance, in combination as Co-amoxiclav (as Amoxicillin-clavulanic acid) which extends its anti-bacterial spectrum.

1 Mar 2013

Exposure to BPA may increase risk of asthma in young children

Researchers at the Columbia Center for Children's Environmental Health at the Mailman School of Public Health are the first to report an association between early childhood exposure to the chemical bisphenol A (BPA) and an elevated risk for asthma in young children. BPA is a component of some plastics and is found in food can liners and store receipts.

1 Mar 2013

Excess of vitamin D during pregnancy can increase risk of food allergy in children

Pregnant women should avoid taking vitamin D supplements. Substitution appears to raise the risk of children developing a food allergy after birth.

28 Feb 2013

National Birth Defects Prevention Network honors BU researcher with Godfrey P. Oakley, Jr., Award

Allen A. Mitchell, MD, a professor of public health (epidemiology) and professor of pediatrics at the Boston University Schools of Public Health and Medicine, recently received the Godfrey P. Oakley, Jr., Award at the annual meeting of the National Birth Defects Prevention Network. Mitchell, who is also the director of Boston University's Slone Epidemiology Center (SEC), was recognized for his significant lifetime contributions to the field of birth defects.

28 Feb 2013

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Complementary medicines include products containing herbs, vitamins, minerals, nutritional supplements, homoeopathic medicines, certain aromatherapy products and traditional Chinese medicines. For this reason they are also called herbal, natural or alternative medicines.

26 Feb 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Mental health risk increased in children with atopic dermatitis

Results from a US study suggest that children with atopic dermatitis (AD) are at significantly increased risk for mental health disorders.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

C-section babies more likely to develop allergies

For expectant moms who may contemplate the pros and cons of natural child birth or Caesarian section, a Henry Ford Hospital study suggests that C-section babies are susceptible to developing allergies by age two.

25 Feb 2013

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

An international team of researchers has found that a once-a-month, high-dose injection of a commonly used asthma drug is highly effective in treating teens and adults chronically afflicted with hives and severe, itchy rash. The drug, omalizumab, was tested on 323 people at 55 medical centers for whom standard antihistamine therapy failed to quell their underlying, allergy-like reaction, known as chronic idiopathic urticaria or chronic spontaneous urticaria.

25 Feb 2013

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

The U.S. Food and Drug Administration is alerting health care providers and patients of a voluntary nationwide recall of all lots of Omontys Injection by Affymax, Inc., of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited, of Deerfield, Ill.

25 Feb 2013

Allergies News and Research

Latest Allergies News and Research

Immunity, Inflammation and Disease journal from Wiley

Eating your greens may be even more important than previously thought

More than 60% of fire ant allergic patients do not adhere to treatment guidelines

DBV Technologies total revenues increase to €2,776,588 for full year 2012

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Amoxicillin effectiveness: an interview with Prof Paul Little, University of Southampton

Exposure to BPA may increase risk of asthma in young children

Excess of vitamin D during pregnancy can increase risk of food allergy in children

National Birth Defects Prevention Network honors BU researcher with Godfrey P. Oakley, Jr., Award

Complementary medicine risks: an interview with Dr Andrew Boyden, NPS MedicineWise

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Mental health risk increased in children with atopic dermatitis

Circassia announces results from ToleroMune cat allergy phase II clinical study

C-section babies more likely to develop allergies

Omalizumab fast, safe and well-tolerated in teens and adults with chronic spontaneous urticaria

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

Race and possibly genetics play a role in children's sensitivity to developing allergies

New data from Boehringer Ingelheim's tiotropium Respimat Phase III UniTinA-asthma programme

UAB becomes first in America to test experimental therapy for emphysema

Washington University creates new type of air-cleaning technology

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Allergies News and Research

Latest Allergies News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in